Compare DexCom, Inc. (DXCM) vs Innovative Industrial Properties Inc (IIPR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Innovative Industrial Properties Inc — how do they compare? DexCom, Inc. trades at $84.11 (market cap $31.86B), while Innovative Industrial Properties Inc trades at $51.83 (market cap $1.43B). The key difference: DexCom, Inc. is far larger — about 22.3× Innovative Industrial Properties Inc's market cap, and Innovative Industrial Properties Inc pays a 14.64% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Innovative Industrial Properties Inc for 86 Days on average.
| DXCM | IIPR | |
|---|---|---|
Market Cap | $31.86B | $1.43B |
Volume | 3,607,070 | 394,222 |
Sector | Health | Real Estate |
52-Week High | $92.34 | $64.67 |
52-Week Low | $54.84 | $44.58 |
Typical Hold Time | 62 Days | 86 Days |
Enterprise Value | $31.32B | $1.96B |
Dividend Yield | — | 14.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.11, down 0.23% on the day, with a bearish technical signal but strong fundamental performance. The company reported Q2 2026 EPS of $0.70, beating expectations, and has shown consistent revenue growth, with 2025 revenue reaching $4.66 billion and net income of $836.3 million. Analyst consensus is strongly bullish with an 80.77% buy rating and a $95.07 price target. Recent news highlights growth opportunities in Type 2 diabetes care and key executive promotions.
The outlook for DXCM is positive due to robust earnings beats, expanding market opportunities, and strong institutional support. However, risks include competitive pressures, reimbursement challenges, and a high valuation with a P/E of 33.38. The stock presents a growth opportunity but requires monitoring of execution against these risks.
IIPR trades at $51.83, up 1.17% on the day, with a bearish technical signal and mixed earnings history. The stock shows attractive valuation ratios, including a P/E of 11.75 and P/B of 0.83, but revenue declined to $265.96M in 2025. Recent news highlights a $245 million mezzanine loan commitment and a quarterly dividend of $1.90, underscoring its REIT structure and focus on cannabis real estate.
The outlook is cautious due to tenant defaults and dividend sustainability concerns, though the stock offers a high yield and potential regulatory catalysts. Risks include sector volatility and financial performance pressures, while analyst consensus leans hold with a $84.67 price target suggesting upside if operational stability improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Innovative Industrial Properties Inc
Innovative Industrial Properties Inc is a real estate investment trust engaged in the acquisition, ownership, and management of specialized industrial properties leased to state-licensed operators for their regulated medical-use cannabis facilities. It conducts its business through a traditional umbrella partnership real estate investment trust, or UPREIT structure, in which properties are owned by Operating Partnership, directly or through subsidiaries. Its property portfolio is spread across the United States.
Read more on IIPR →
